<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04163601</url>
  </required_header>
  <id_info>
    <org_study_id>RECHMPL19_0487</org_study_id>
    <nct_id>NCT04163601</nct_id>
  </id_info>
  <brief_title>Liposomal Amikacin Inhalation in M.Abscessus Patients</brief_title>
  <official_title>NTM-net Study: Liposomal Amikacin Inhalation in M.Abscessus Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European network (http://www.ntm-net.org/index.php/ntm-net)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Mycobacterium abscessus is one of the many species of non-tuberculous mycobacteria. M.
      abscessus infections are known to be common in patients with cystic fibrosis (CF).
      Mycobacterium abscessus yields poor cure rates. Liposomal amikacin inhalation (LAI) might be
      a good alternative for intravenous treatment as the first results with mycobacterium avium
      treatment yield good results.

      The objective of this study is to summarize the clinical data of patients with M.abscessus
      treated with LAI on compassionate use basis to assess treatment outcomes
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 30, 2019</start_date>
  <completion_date type="Anticipated">March 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>culture conversion</measure>
    <time_frame>1 day</time_frame>
    <description>Main study endpoints will consist of microbiological cure, clinical cure and treatment culture conversion at the end of treatment. Treatment outcome definitions according to the NTM net consensus are used</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>clinical cure</measure>
    <time_frame>1 day</time_frame>
    <description>Main study endpoints will consist of microbiological cure, clinical cure and treatment culture conversion at the end of treatment. Treatment outcome definitions according to the NTM net consensus are used</description>
  </secondary_outcome>
  <enrollment type="Anticipated">400</enrollment>
  <condition>M.Abscessus Pulmonary Disease</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed with M. abscessus disease
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

        In order to be eligible to participate in this study, a subject must meet all of the
        following criteria:

          -  ATS diagnostic criteria for M.abscessus pulmonary disease

          -  &gt; 12 years

          -  Patients with CF/COPD or other underlying disease

          -  LAI use for more than 3 weeks

        Exclusion criteria

        A potential subject who meets any of the following criteria will be excluded from
        participation in this study:

        â€¢ Extra-pulmonary or disseminated disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raphael CHIRON, PU-PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospitals of Montpellier</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Raphael CHIRON, PU-PH</last_name>
    <phone>467336089</phone>
    <phone_ext>33</phone_ext>
    <email>c-chiron@chu-montpellier.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Uh Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>RAPHAEL CHIRON, PU-PH</last_name>
      <phone>467336089</phone>
      <phone_ext>33</phone_ext>
      <email>c-chiron@chu-montpellier.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 13, 2019</study_first_submitted>
  <study_first_submitted_qc>November 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 15, 2019</study_first_posted>
  <last_update_submitted>February 11, 2020</last_update_submitted>
  <last_update_submitted_qc>February 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>NC</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

